Report

  1. Home
  2. Discounted reports

North America Ophthalmic Drugs Market Forecast 2023-2032

Market Report I 2023-11-17 I 161 Pages I Inkwood Research
Discounted by 20% to 2024-05-30

KEY FINDINGS
The North America ophthalmic drugs market is projected to record a CAGR of 5.56% during the forecast period, 2023-2032. Growing awareness of eye health and the accessibility of eye care services are fostering early detection and treatment of eye conditions. This pattern is fueling the expansion of the ophthalmic drugs market in North America.
MARKET INSIGHTS
Canada and the United States are evaluated for the North America ophthalmic drugs market growth assessment. The surge in eye diseases, particularly those associated with aging and lifestyle, is fueling the need for ophthalmic drugs. Progress in drug delivery technologies is amplifying drug effectiveness and patient adherence, contributing to market expansion. With an increasing elderly population in the United States, there is a heightened vulnerability to age-related eye conditions, driving up the demand for ophthalmic drugs. The pharmaceutical industry's dedication to research and development is yielding the creation of advanced ophthalmic drugs, marking a significant stride forward.
The ophthalmic drugs market in the United States is dominated by key players such as Novartis AG, Allergan (now a part of AbbVie Inc), Regeneron Pharmaceuticals, Santen Pharmaceutical Co Ltd, and Bausch Health Companies Inc. These industry leaders consistently invest in research and development, aiming to introduce novel and advanced ophthalmic drugs to the market. This ongoing commitment plays a pivotal role in fostering the growth and progression of eye care in the United States.
COMPETITIVE INSIGHTS
Some of the leading players in the North America ophthalmic drugs market include Bausch Health Companies Inc, Pfizer Inc, AbbVie Inc, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation caters to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. EMERGING THERAPIES FOR DRY EYE SYNDROME
2.5.2. GROWING DEMAND FOR COMBINATION THERAPIES
2.5.3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
2.5.4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. AGING POPULATION'S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
3.1.2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
3.1.3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
3.1.4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
3.2. KEY RESTRAINTS
3.2.1. DELAY IN DRUG APPROVALS
3.2.2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.2. TECHNOLOGY SNAPSHOT
4.2.1. BIOLOGICS
4.2.2. CELL THERAPY
4.2.3. GENE THERAPY
4.2.4. DRUG DELIVERY
4.2.5. SMALL MOLECULE
4.2.6. OTHER TECHNOLOGIES
4.3. PORTER'S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. KEY BUYING CRITERIA
4.8. REGULATORY FRAMEWORK
5. MARKET BY INDICATION
5.1. DRY EYE
5.2. GLAUCOMA
5.3. INFECTION/INFLAMMATION/ALLERGIES
5.4. RETINAL DISORDER
5.4.1. WET AGE-RELATED MACULAR DEGENERATION
5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
5.4.3. DIABETIC RETINOPATHY
5.4.4. OTHER RETINAL DISORDERS
5.5. OTHER INDICATIONS
6. MARKET BY TYPE
6.1. PRESCRIPTION DRUGS
6.2. OVER-THE-COUNTER DRUGS
7. MARKET BY DOSAGE FORM
7.1. GELS
7.2. EYE SOLUTIONS & SUSPENSIONS
7.3. CAPSULES & TABLETS
7.4. EYE DROPS
7.5. OINTMENTS
8. MARKET BY THERAPEUTIC CLASS
8.1. ANTI-GLAUCOMA
8.2. ANTI-INFECTION
8.3. ANTI-INFLAMMATORY
8.4. ANTI-ALLERGY
8.5. OTHER THERAPEUTIC CLASSES
9. MARKET BY DISTRIBUTION CHANNEL
9.1. HOSPITAL PHARMACIES
9.2. DRUG STORES
9.3. ONLINE PHARMACIES
9.4. OTHER DISTRIBUTION CHANNELS
10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. NORTH AMERICA OPHTHALMIC DRUGS MARKET DRIVERS
10.1.3. NORTH AMERICA OPHTHALMIC DRUGS MARKET CHALLENGES
10.1.4. KEY PLAYERS IN NORTH AMERICA OPHTHALMIC DRUGS MARKET
10.1.5. COUNTRY ANALYSIS
10.1.5.1. UNITED STATES
10.1.5.1.1. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
10.1.5.2. CANADA
10.1.5.2.1. CANADA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGERS & ACQUISITIONS
11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
11.1.3. PARTNERSHIPS & AGREEMENTS
11.2. COMPANY PROFILES
11.2.1. ABBVIE INC
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCTS & SERVICES
11.2.1.3. STRENGTHS & CHALLENGES
11.2.2. ACCUTOME INC
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCTS & SERVICES
11.2.2.3. STRENGTHS & CHALLENGES
11.2.3. BAUSCH HEALTH COMPANIES INC
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCTS & SERVICES
11.2.3.3. STRENGTHS & CHALLENGES
11.2.4. GENENTECH INC
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCTS & SERVICES
11.2.4.3. STRENGTHS & CHALLENGES
11.2.5. JOHNSON & JOHNSON
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCTS & SERVICES
11.2.5.3. STRENGTHS & CHALLENGES
11.2.6. THEA PHARMA INC
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCTS & SERVICES
11.2.6.3. STRENGTHS & CHALLENGES
11.2.7. NOVARTIS AG
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCTS & SERVICES
11.2.7.3. STRENGTHS & CHALLENGES
11.2.8. PFIZER INC
11.2.8.1. COMPANY OVERVIEW
11.2.8.2. PRODUCTS & SERVICES
11.2.8.3. STRENGTHS & CHALLENGES
11.2.9. REGENERON PHARMACEUTICALS INC
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCTS & SERVICES
11.2.9.3. STRENGTHS & CHALLENGES
11.2.10. SANTEN PHARMACEUTICAL CO LTD
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCTS & SERVICES
11.2.10.3. STRENGTHS & CHALLENGES
11.2.11. SUN PHARMACEUTICAL INDUSTRIES LTD
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCTS & SERVICES
11.2.11.3. STRENGTHS & CHALLENGES
11.2.12. TEVA PHARMACEUTICALS INDUSTRIES LTD
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCTS & SERVICES
11.2.12.3. STRENGTHS & CHALLENGES


LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - OPHTHALMIC DRUGS
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 5: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 7: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 8: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 9: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 10: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 11: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 12: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 13: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 14: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 15: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 16: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 17: KEY PLAYERS OPERATING IN NORTH AMERICA OPHTHALMIC DRUGS MARKET
TABLE 18: LIST OF MERGERS & ACQUISITIONS
TABLE 19: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 20: LIST OF PARTNERSHIPS & AGREEMENTS


LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY INDICATION, IN 2022
FIGURE 7: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2032 (IN $ MILLION)
FIGURE 8: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2032 (IN $ MILLION)
FIGURE 9: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INFECTION/INFLAMMATION/ALLERGIES, 2023-2032 (IN $ MILLION)
FIGURE 10: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2032 (IN $ MILLION)
FIGURE 11: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY RETINAL DISORDER, IN 2022
FIGURE 12: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)
FIGURE 13: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)
FIGURE 14: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY, 2023-2032 (IN $ MILLION)
FIGURE 15: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS, 2023-2032 (IN $ MILLION)
FIGURE 16: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER INDICATIONS, 2023-2032 (IN $ MILLION)
FIGURE 17: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
FIGURE 18: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 19: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 20: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DOSAGE FORM, IN 2022
FIGURE 21: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2032 (IN $ MILLION)
FIGURE 22: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS & SUSPENSIONS, 2023-2032 (IN $ MILLION)
FIGURE 23: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS, 2023-2032 (IN $ MILLION)
FIGURE 24: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2032 (IN $ MILLION)
FIGURE 25: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2032 (IN $ MILLION)
FIGURE 26: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY THERAPEUTIC CLASS, IN 2022
FIGURE 27: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2032 (IN $ MILLION)
FIGURE 28: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2032 (IN $ MILLION)
FIGURE 29: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY, 2023-2032 (IN $ MILLION)
FIGURE 30: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2032 (IN $ MILLION)
FIGURE 31: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC CLASSES, 2023-2032 (IN $ MILLION)
FIGURE 32: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022
FIGURE 33: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 34: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2032 (IN $ MILLION)
FIGURE 35: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 36: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER DISTRIBUTION CHANNELS, 2023-2032 (IN $ MILLION)
FIGURE 37: NORTH AMERICA OPHTHALMIC DRUGS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
FIGURE 38: UNITED STATES OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 39: CANADA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE